RSCM
INZY

Rock Springs Capital Management’s Inozyme Pharma INZY Stock Holding History

Rock Springs Capital Management’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,445,299
Closed -$3.14M – 96
2025
Q1 		$3.14M Sell
3,445,299
-416,684
-11% -$578K 0.18% 72
2024
Q4 		$10.7M Buy
3,861,983
+59,100
+2% +$225K 0.41% 60
2024
Q3 		$19.9M Buy
3,802,883
+104,509
+3% +$542K 0.65% 51
2024
Q2 		$16.5M Buy
3,698,374
+17,200
+0.5% +$83.4K 0.5% 55
2024
Q1 		$28.2M Hold
3,681,174
– – 0.72% 48
2023
Q4 		$15.7M Hold
3,681,174
– – 0.39% 63
2023
Q3 		$15.5M Buy
3,681,174
+253,090
+7% +$1.29M 0.41% 64
2023
Q2 		$19.1M Buy
3,428,084
+213,184
+7% +$1.26M 0.45% 58
2023
Q1 		$18.4M Buy
3,214,900
+128,873
+4% +$341K 0.44% 59
2022
Q4 		$3.24M Buy
3,086,027
+278,409
+10% +$487K 0.08% 97
2022
Q3 		$7.52M Buy
2,807,618
+167,562
+6% +$606K 0.19% 89
2022
Q2 		$12.6M Buy
2,640,056
+1,446,861
+121% +$6.29M 0.37% 68
2022
Q1 		$4.88M Buy
1,193,195
+324,729
+37% +$1.91M 0.12% 105
2021
Q4 		$5.92M Buy
868,466
+18,451
+2% +$159K 0.14% 114
2021
Q3 		$9.85M Buy
850,015
+9,743
+1% +$152K 0.21% 106
2021
Q2 		$14.3M Buy
840,272
+12,372
+1% +$215K 0.28% 96
2021
Q1 		$16.4M Sell
827,900
-2,646
-0.3% -$58.4K 0.36% 79
2020
Q4 		$17.1M Sell
830,546
-49,408
-6% -$1.18M 0.36% 85
2020
Q3 		$23.1M Buy
+879,954
New +$21.9M 0.59% 57

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Rock Springs Capital Management's INZY Position: Q2 2025 in Review

Rock Springs Capital Management sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 3,445,299 shares — an estimated $3.14M sold.

Rock Springs Capital Management first reported a position in INZY in Q3 2020 and held it in 19 quarters. The position peaked at $28.2M in Q1 2024. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • Rock Springs Capital Management reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • Rock Springs Capital Management sold 3,445,299 Inozyme Pharma shares in Q2 2025, an estimated $3.14M.
  • Rock Springs Capital Management first reported a position in Inozyme Pharma in Q3 2020 and held it in 19 quarters.
  • Rock Springs Capital Management's Inozyme Pharma position peaked at $28.2M in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on Rock Springs Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.